• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

BPH treatment offers promising 2-year results

Article

An investigational therapy for BPH known as NX-1207 has shown positive results in a long-term outcome study, according to its manufacturer, Nymox Pharmaceutical Corp.

An investigational therapy for BPH known as NX-1207 has shown positive results in a long-term outcome study, according to its manufacturer, Nymox Pharmaceutical Corp.

Twenty-four clinical trial sites across the United States and 103 unselected subjects participated in the blinded, placebo-controlled study.

The study assessed symptom scores and treatment outcome 2 years (range, 16 to 27 months) after a single treatment with NX-1207 or placebo. At the time of follow-up, 52% of patients treated with NX-1207 were not on BPH medication and had not required surgical intervention for their BPH since their initial treatment with NX-1207; these patients had a mean improvement of 10.2 points in AUA BPH Symptom Score values.

For patients with prostates <70 grams, the results showed that a statistically significant percentage of patients initially treated once with NX-1207 were not on BPH medication and had not required surgical intervention compared with patients who received placebo. In this population, the results showed that 60% of patients who received NX-1207 required no other BPH treatment and had maintained an improvement of 11.3 points in BPH symptom score (p<.05 vs. placebo).

Related Videos
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 4 experts on prostate cancer
Related Content
© 2024 MJH Life Sciences

All rights reserved.